Guardant Health, Inc. (NASDAQ:GH) Shares Acquired by US Bancorp DE

US Bancorp DE raised its stake in Guardant Health, Inc. (NASDAQ:GH) by 33.8% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 33,022 shares of the company’s stock after purchasing an additional 8,346 shares during the quarter. US Bancorp DE’s holdings in Guardant Health were worth $758,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in the stock. Vanguard Group Inc. raised its holdings in Guardant Health by 2.7% in the first quarter. Vanguard Group Inc. now owns 11,436,026 shares of the company’s stock valued at $235,925,000 after buying an additional 305,372 shares during the period. Bank of New York Mellon Corp increased its position in shares of Guardant Health by 31.8% in the second quarter. Bank of New York Mellon Corp now owns 1,280,221 shares of the company’s stock worth $36,973,000 after acquiring an additional 309,157 shares in the last quarter. Railway Pension Investments Ltd raised its stake in shares of Guardant Health by 63.8% in the 2nd quarter. Railway Pension Investments Ltd now owns 620,878 shares of the company’s stock valued at $17,931,000 after acquiring an additional 241,800 shares during the period. abrdn plc lifted its holdings in shares of Guardant Health by 47.9% during the 3rd quarter. abrdn plc now owns 552,473 shares of the company’s stock valued at $12,674,000 after acquiring an additional 178,882 shares in the last quarter. Finally, ARK Investment Management LLC boosted its position in Guardant Health by 25.6% during the 2nd quarter. ARK Investment Management LLC now owns 453,590 shares of the company’s stock worth $13,100,000 after purchasing an additional 92,424 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have weighed in on GH. Craig Hallum upped their price target on Guardant Health from $28.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. UBS Group raised their price target on shares of Guardant Health from $32.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, August 21st. Bank of America lifted their price target on shares of Guardant Health from $28.00 to $40.00 and gave the stock a “buy” rating in a research note on Thursday, July 18th. BTIG Research upped their price objective on shares of Guardant Health from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, July 30th. Finally, The Goldman Sachs Group lifted their target price on Guardant Health from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday. One equities research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, Guardant Health presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.75.

Guardant Health Stock Performance

Shares of GH stock opened at $28.61 on Friday. The business has a 50 day simple moving average of $23.13 and a 200 day simple moving average of $26.04. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.40 and a quick ratio of 6.07. The firm has a market capitalization of $3.52 billion, a price-to-earnings ratio of -6.75 and a beta of 1.11. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $37.04.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.10). Guardant Health had a negative net margin of 74.02% and a negative return on equity of 660.24%. The company had revenue of $177.24 million during the quarter, compared to the consensus estimate of $162.59 million. During the same quarter last year, the business earned ($0.67) earnings per share. The company’s revenue was up 29.2% on a year-over-year basis. On average, equities research analysts anticipate that Guardant Health, Inc. will post -3.31 EPS for the current year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.